Magnetic Bead Fluorescent Immunoassay Detects Novel Inflammation Marker
By LabMedica International staff writers Posted on 12 Jan 2016 |
A magnetic bead fluorescent sandwich immunoassay has been developed that allows rapid serum measurement of the novel inflammation marker at the point of care (POC) that could aid pneumonia diagnosis.
Pneumonia is an acute infection caused by various bacteria and virus species and the disease is characterized by augmented bronchoalveolar liquid and pus congesting the respiratory tract, resulting in shortness of breath.
Scientists at the Technische Universität München (Munich, Germany) obtained healthy blood donor sera, and patient sera were collected from those with radiologically confirmed pneumonia. A rapid and simple magnetic bead-based immunoassay was developed for the detection of the novel biomarker chitinase-3-like protein 1 (CHI3L1), and also known as YKL40, in an innovative POC-ready device for assistance in the diagnosis of pneumonia.
The study was performed using the ESE Quant Tube Scanner device (QIAGEN Lake Constance GmbH; Stockach Germany). Excitation and emission wavelengths were adjusted to 625 and 680 nm, respectively, to fit the spectral properties of the fluorescent 7-hydroxy-9H-(1,3-dichloro-9,9-dimethylacridin-2-one (DDAO). The ESE Quant Tube Scanner uses a confocal microfluorescence reader, which is small enough to be automatically positioned under each tube. The measurement is repeated every 20 seconds, leading to the recording of the time course of substrate turnover.
The assay procedure, from sample addition to data retrieval, consists of three steps and is performed in less than 20 minutes. The assay has a linear range from 3 ng/mL to 111 ng/mL, with a limit of detection of 2.9 ng/mL. The average recoveries were found between 101 and 111%. The mean calculated serum concentration of patients with pneumonia was 334 ng/mL ± 225 ng/mL (median 300 ng/mL, range 107–821 ng/mL), while serum samples from healthy donors averaged at 50 ng/mL ± 49 ng/mL (median 35 ng/mL, range 9–199 ng/mL).
The authors concluded that the magnetic bead fluorescence immunoassay is a proof of concept that can accurately and rapidly receive protein biomarker data using antibodies bound to magnetic beads in a POC-ready device, providing a simple alternative immunoassay that could help optimize pneumonia diagnosis in low resource settings. The key features of the presented assay are a rapid fluorescence measurement below 20 minutes, a detection limit that corresponds well to the lower reference range of this inflammation serum marker, and usage of an inexpensive and robust device. The study was published in the December 2015 issue of the Journal of Immunological Methods.
Related Links:
Technische Universität München
QIAGEN Lake Constance GmbH
Pneumonia is an acute infection caused by various bacteria and virus species and the disease is characterized by augmented bronchoalveolar liquid and pus congesting the respiratory tract, resulting in shortness of breath.
Scientists at the Technische Universität München (Munich, Germany) obtained healthy blood donor sera, and patient sera were collected from those with radiologically confirmed pneumonia. A rapid and simple magnetic bead-based immunoassay was developed for the detection of the novel biomarker chitinase-3-like protein 1 (CHI3L1), and also known as YKL40, in an innovative POC-ready device for assistance in the diagnosis of pneumonia.
The study was performed using the ESE Quant Tube Scanner device (QIAGEN Lake Constance GmbH; Stockach Germany). Excitation and emission wavelengths were adjusted to 625 and 680 nm, respectively, to fit the spectral properties of the fluorescent 7-hydroxy-9H-(1,3-dichloro-9,9-dimethylacridin-2-one (DDAO). The ESE Quant Tube Scanner uses a confocal microfluorescence reader, which is small enough to be automatically positioned under each tube. The measurement is repeated every 20 seconds, leading to the recording of the time course of substrate turnover.
The assay procedure, from sample addition to data retrieval, consists of three steps and is performed in less than 20 minutes. The assay has a linear range from 3 ng/mL to 111 ng/mL, with a limit of detection of 2.9 ng/mL. The average recoveries were found between 101 and 111%. The mean calculated serum concentration of patients with pneumonia was 334 ng/mL ± 225 ng/mL (median 300 ng/mL, range 107–821 ng/mL), while serum samples from healthy donors averaged at 50 ng/mL ± 49 ng/mL (median 35 ng/mL, range 9–199 ng/mL).
The authors concluded that the magnetic bead fluorescence immunoassay is a proof of concept that can accurately and rapidly receive protein biomarker data using antibodies bound to magnetic beads in a POC-ready device, providing a simple alternative immunoassay that could help optimize pneumonia diagnosis in low resource settings. The key features of the presented assay are a rapid fluorescence measurement below 20 minutes, a detection limit that corresponds well to the lower reference range of this inflammation serum marker, and usage of an inexpensive and robust device. The study was published in the December 2015 issue of the Journal of Immunological Methods.
Related Links:
Technische Universität München
QIAGEN Lake Constance GmbH
Read the full article by registering today, it's FREE!

Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!

Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Immunology News
- Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
- Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
- Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
- Cerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
- New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
- Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
- Novel Analytical Method Tracks Progression of Autoimmune Diseases
- 3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response
- Blood Test for Fungal Infections Could End Invasive Tissue Biopsies
- Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies
- New Discovery in Blood Immune Cells Paves Way for Parkinson's Disease Diagnostic Test
- AI Tool Uses Routine Blood Tests to Predict Immunotherapy Response for Various Cancers
- Blood Test Can Predict How Long Vaccine Immunity Will Last
- Microfluidic Chip-Based Device to Measure Viral Immunity
Channels
Clinical Chemistry
view channel
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more
New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
"Liquid biopsy" technology, which relies on blood tests for early cancer detection and monitoring cancer burden in patients, has the potential to transform cancer care. However, detecting the mutational... Read more
"Metal Detector" Algorithm Hunts Down Vulnerable Tumors
Scientists have developed an algorithm capable of functioning as a "metal detector" to identify vulnerable tumors, marking a significant advancement in personalized cancer treatment. This breakthrough... Read more
Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
Pancreatic cancer is often asymptomatic in its early stages, making it difficult to detect until it has progressed. Consequently, only 15% of pancreatic cancers are diagnosed early enough to allow for... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more